CRISPRoff and CRISPRon Epigenetic Editing: Molecular Mechanisms and Therapeutic Applications
Main Article Content
Keywords
CRISPRoff, CRISPRon, Epigenetic editing, Gene regulation, Therapeutic applications
Abstract
Epigenetic modification plays a key role in gene regulation. CRISPRoff and CRISPRon, based on Nuclease-dead Cas9 (dCas9), can achieve precise, reversible regulation of gene expression without changing the DNA sequence, which is better than traditional cutting technology. This article systematically compares the two sets of systems. At the molecular level, the differences in composition and mechanism between the two are analyzed. CRISPRoff achieves long-lasting silencing through the coordinated activity of its effector domains writing trimethylation of histone H3 at lysine 9 (H3K9me3) and DNA methylation; CRISPRon achieves reversible activation through demethylation and collaborative transcription activation. On this basis, this article reviews the application of the two in disease treatment, including CRISPRoff targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the treatment of familial hypercholesterolemia (FH), CRISPRon targeting the Forkhead Box P3 (FOXP3) Regulatory T-Cell-Specific Demethylated Region (TSDR) demethylation to stabilize regulatory T cells (Tregs) and exploring the synergistic prospects of the two in chimeric antigen receptor T-cell (CAR-T cell) remodeling. This article clarifies the applicable boundaries and complementary relationship between the two and provides a theoretical direction for tool selection and collaborative strategies. However, there are still problems to be solved in this field, such as in vivo collaborative application and delivery efficiency. Future research should focus on the development of efficient delivery systems and verify the feasibility of collaborative strategies in in vivo models to promote clinical transformation.
References
- [1] Yahsi, B., Palaz, F., & Dincer, P. (2024). Applications of CRISPR Epigenome Editors in Tumor Immunology and Autoimmunity. ACS synthetic biology, 13(2), 413–427. https://doi.org/10.1021/acssynbio.3c00524
- [2] Nuñez, J. K., Chen, J., Pommier, G. C., Cogan, J. Z., Replogle, J. M., Adriaens, C., Ramadoss, G. N., Shi, Q., Hung, K. L., Samelson, A. J., Pogson, A. N., Kim, J. Y. S., Chung, A., Leonetti, M. D., Chang, H. Y., Kampmann, M., Bernstein, B. E., Hovestadt, V., Gilbert, L. A., & Weissman, J. S. (2021). Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell, 184(9), 2503–2519.e17. https://doi.org/10.1016/j.cell.2021.03.025
- [3] Wu, X., & Zhang, Y. (2017). TET-mediated active DNA demethylation: mechanism, function and beyond. Nature reviews. Genetics, 18(9), 517–534. https://doi.org/10.1038/nrg.2017.33
- [4] Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., Ter-Ovanesyan, D., Braff, J. L., Davidsohn, N., Housden, B. E., Perrimon, N., Weiss, R., Aach, J., Collins, J. J., & Church, G. M. (2015). Highly efficient Cas9-mediated transcriptional programming. Nature methods, 12(4), 326–328. https://doi.org/10.1038/nmeth.3312
- [5] Mansfield, B. S., Bene-Alhasan, Y., Ballantyne, C. M., & Raal, F. J. (2026). The evolving therapeutic landscape of PCSK9 inhibition. Atherosclerosis, 414, 120670. https://doi.org/10.1016/j.atherosclerosis.2026.120670
- [6] Tremblay, F., Xiong, Q., Shah, S. S., Ko, C. W., Kelly, K., Morrison, M. S., Giancarlo, C., Ramirez, R. N., Hildebrand, E. M., Voytek, S. B., El Sebae, G. K., Wright, S. H., Lofgren, L., Clarkson, S., Waters, C., Linder, S. J., Liu, S., Eom, T., Parikh, S., Weber, Y., … Jaffe, A. B. (2025). A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels. Nature medicine, 31(4), 1329–1338. https://doi.org/10.1038/s41591-025-03508-x
- [7] Goudy, L., Ha, A., Borah, A. A., Umhoefer, J. M., Chow, L., Tran, C., Winters, A., Talbot, A., Hernandez, R., Li, Z., Subramanya, S., Arab, A., Kale, N., Lee, J. H. J., Muldoon, J. J., Liu, C., Schmidt, R., Santangelo, P., Carnevale, J., Eyquem, J., … Gilbert, L. A. (2025). Integrated epigenetic and genetic programming of primary human T cells. Nature biotechnology, 10.1038/s41587-025-02856-w. Advance online publication. https://doi.org/10.1038/s41587-025-02856-w
- [8] Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152(5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
- [9] Sobocińska, J., Molenda, S., Machnik, M., & Oleksiewicz, U. (2021). KRAB-ZFP Transcriptional Regulators Acting as Oncogenes and Tumor Suppressors: An Overview. International journal of molecular sciences, 22(4), 2212. https://doi.org/10.3390/ijms22042212
- [10] Jia, D., Jurkowska, R. Z., Zhang, X., Jeltsch, A., & Cheng, X. (2007). Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature, 449(7159), 248–251. https://doi.org/10.1038/nature06146
- [11] Yuan, L., Sun, B., Xu, L., Chen, L., & Ou, W. (2021). The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma. International journal of molecular sciences, 22(14), 7416. https://doi.org/10.3390/ijms22147416
- [12] Binda, O., LeRoy, G., Bua, D. J., Garcia, B. A., Gozani, O., & Richard, S. (2010). Trimethylation of histone H3 lysine 4 impairs methylation of histone H3 lysine 9: regulation of lysine methyltransferases by physical interaction with their substrates. Epigenetics, 5(8), 767–775. https://doi.org/10.4161/epi.5.8.13278
- [13] Guo, X., Wang, L., Li, J., Ding, Z., Xiao, J., Yin, X., He, S., Shi, P., Dong, L., Li, G., Tian, C., Wang, J., Cong, Y., & Xu, Y. (2015). Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature, 517(7536), 640–644. https://doi.org/10.1038/nature13899
- [14] Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., Nureki, O., & Zhang, F. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature, 517(7536), 583–588. https://doi.org/10.1038/nature14136
- [15] Blais, J. E., Zhong, W., Li, C. Y. V., Kongkaew, C., & Chan, A. H. Y. (2026). Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. JACC. Advances, 5(5), 102733. https://doi.org/10.1016/j.jacadv.2026.102733
- [16] Chen, K. Y., Kibayashi, T., Giguelay, A., Hata, M., Nakajima, S., Mikami, N., Takeshima, Y., Ichiyama, K., Omiya, R., Ludwig, L. S., Hattori, K., & Sakaguchi, S. (2025). Genome-wide CRISPR screen in human T cells reveals regulators of FOXP3. Nature, 642(8066), 191–200. https://doi.org/10.1038/s41586-025-08795-5
- [17] Carnevale, J., Shifrut, E., Kale, N., Nyberg, W. A., Blaeschke, F., Chen, Y. Y., Li, Z., Bapat, S. P., Diolaiti, M. E., O'Leary, P., Vedova, S., Belk, J., Daniel, B., Roth, T. L., Bachl, S., Anido, A. A., Prinzing, B., Ibañez-Vega, J., Lange, S., Haydar, D., … Marson, A. (2022). RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature, 609(7925), 174–182. https://doi.org/10.1038/s41586-022-05126-w
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.